Vesicant characteristics of oxapliplatin following antecubital extravasation

Clinical Oncology

Volumn 15, Issue 5, 2003, Pages 237-239

  Kennedy, J G ^a   Donahue, J P ^a   Hoang, B ^a   Boland, P J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Extravasation; Oxaliplatin

Indexed keywords

ANTHRACYCLINE; CELECOXIB; CISPLATIN; FLUOROURACIL; FLUOROURACIL CALCIUM; FLUOROURACIL DERIVATIVE; FOLINIC ACID; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PACLITAXEL; PLATINUM; SODIUM THIOSULFATE; SULFOXIDE; UNCLASSIFIED DRUG; VANCOMYCIN; VINCA ALKALOID; ANTINEOPLASTIC AGENT; IRRITANT AGENT; PLATINUM COMPLEX;

ADULT; ARTICLE; AUDITORY SYSTEM FUNCTION; CANCER SURGERY; CASE REPORT; DECISION MAKING; DRUG EXTRAVASATION; DRUG POTENTIATION; DRUG SAFETY; ELBOW; FEMALE; HUMAN; JOINT FUNCTION; LIVER TOXICITY; MEDICAL DOCUMENTATION; MUSCLE DISEASE; MUSCLE NECROSIS; MYOFIBROSIS; NEPHROTOXICITY; PHYSIOTHERAPY; PRIORITY JOURNAL; RECTUM CARCINOMA; SENSORY DYSFUNCTION; SOFT TISSUE DISEASE; SOFT TISSUE INJURY; SUBCUTANEOUS TISSUE; ADENOCARCINOMA; CONTRAST MEDIUM EXTRAVASATION; MIDDLE AGED; RECTUM TUMOR;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; EXTRAVASATION OF DIAGNOSTIC AND THERAPEUTIC MATERIALS; FEMALE; HUMANS; IRRITANTS; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RECTAL NEOPLASMS;

EID: 0042130339     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0936-6555(02)00338-2     Document Type: Article

References (19)

1. Ignoffo RJ, Friedman MA. Therapy of local toxities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 1980;7:17-27.
2. Ulrich-Pur H, Fiebiger WC, Schull B, Korneck GV, Scheithauer W, Raderer M. Oxaliplating-induced fever and release of IL6. Oncology 2000;59:187-189.
3. Pelley RJ. Oxaliplatin: A new agent for colorectal cancer. Curr Oncol Rep 2001;3:147-155.
4. Levi F, Misset JL, Brienza S, et al. A chronopharmacological phase II clinical trial with 5-flourouracil, folinic acid and oxaliplatin using an ambulatory multichannel, multiprogrammable pump: high anti-tumor effectiveness against metastatic colorectal cancer. Eur J Cancer 1997;33:214-219.
5. Baur M, Kienzr HR, Rath Z, Dittrich C. Extravasation of oxaliplatin (Eloxatin R) - clinical course. Onkologie 2000;23:468-471.
6. Rudolph R, Larson DL. Aetiology and treatment of chemotherapeutic agent extravasation injuries. A review. J Clin Oncol 1987;5:1116-1126.
7. Fuller B, Lind M, Bonomi P. Mitomycin C extravasation exacerbated by sunlight. Arch Intern Med 1981;94:452.
8. Argenta LC, Manders EK. Mitomycin C extravasation injuries. Cancer 1983;51:1080-1082.
9. Rudolph R, Stein RS, Patillo R. Skin ulcers due to adriamycin. Cancer 1976;38:1087-1094.
10. Rudolph R, Woodward M, Hurn I. Ultrastructure of doxyrubicin induced skin ulcers in rats. Cancer Res 1879;39:3689-3693.
11. Bowers DG, Lynch JB. Adriamycin extravasation. Plast Reconstr Surg 1978;61:86-92.
12. Bertelli G. Prevention and management of extravasation of cytotoxic drugs. Drug Safety 1995;14:245-255.
13. Bairey O, Jihad B, Bracha S, Mati S. Severe tissue necrosis after cisplatin extravasation at low concentration: possible immediate recall phenomenon. J Natl Cancer Inst 1997;89:1233-1234.
14. Larson DL. What is the appropriate treatment of tissue extravasation by antitumor agents? Plast Reconstr Surg 1985;75: 397-405.
15. Larson DL. Treatment of tissue extravasation by antitumor agents. Cancer 1982;49:1796-1799.
16. Preuss P, Partoft S. Cytostatic extravasations. Ann Plast Surg 1987; 19:323-329.
17. Laughlin RA, Landeen JM, Habal MB. The management of inadvertent subcutaneous adriamycin infiltration. Am J Surg 1980; 137:408-412.
18. Dorr RT. Antidotes to chemotherapy extravasation. Blood Rev 1990;4:41-60.
19. Comas D, Mateu J. Treatment of extravasation of both doxorubicin and vincristine administration in a Y-site infusion. Ann Pharmacother 1996;30:244-246.